MedTrace Logo

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

NCT03386448 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-05-20

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical trial is to determine the safety and efficacy of scopolamine utilized in conjunction with naltrexone for the treatment of major depression.

Conditions

Interventions

DRUG

Scopolamine and naltrexone

participants will receive scopolamine and naltrexone in buccal drops

DRUG

placebo arm

participants will receive placebo medications

Sponsors & Collaborators

  • The Taub Group

    lead INDUSTRY

Principal Investigators

  • Neal Taub · The Taub Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-11-20
Completion
2018-11-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03386448 on ClinicalTrials.gov